The as-prepared nanomedicine enables efficient co-delivery of nucleic acid therapeutics and chemotherapeutics to xenograft tumors, leading to obvious multidrug resistance protein 1 (MDR1) gene expression inhibition, enhanced intracellular accumulation of DOX, and potentiated apoptosis, and thus improved tumor treatment efficacy. The gene discussed is ABCB1; the disease is neoplasm.